Since 177Lu-PSMA-617 was experimental salvage treatment following failure of individually appropriate conventional therapies, patients were generally elderly and heavily pretreated (median age 70 years; prior taxanes 74.0%, 188/254), with late–end-stage disease (visceral metastasis in 32.7%, 83/...
241924 Introduction: [177Lu]Lu-PSMA-617 (LuPSMA) radioligand therapy improves survival and quality-of-life (QOL) in patients with metastatic castration-resistant prostate cancer (mCRPC). A majority of patients experience clinically significant PSA decline after the first LuPSMA cycle. We assessed ...
Lutetium-177 prostate-specific membrane antigen-617 (177Lu-PSMA-617) in end-stage metastatic castration-resistant prostate cancer (mCRPC) has reported favourable outcomes. In this study, we aimed to prospectively compare the efficacy and safety of 177Lu-PSMA-617 and docetaxel in chemotherapy-naïve...
VISION研究探究了177Lu-PSMA-617这种β-发射体,它能够靶向表达PSMA的细胞,并发现在先前已接受多种治疗方案的mCRPC患者中能够延长总生存期,而且具有可接受的安全性(3)。另一种177Lu-PSMA放射性配体(177Lu-PSMA-I&T)的耐受性也很好,...
received up to four cycles of intravenous LuPSMA, according to tumour burden, with a mean administered radioactivity of 7.5 GBq per cycle. “We elected to adjust the amount of radioactivity based on tumour volume, renal function and body weight, adapted from our protocols using177Lu to treat ...
177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol ... Sahoo,Ranjit,Kumar,... - 《European Journal of Nuclear Medicine & Molecular Imaging》 被引量: 0发表: 2017年 Lu-177-DKFZ-PSMA-617 therap...
In this study, 101 patients received cabazitaxel, and 99 received Lu-PSMA. The 66% of patients in the Lu-PSMA group showed a PSA decline of more than 50%, compared to only 37% in the cabazitaxel group (P < 0.0001). However, a recently published study from the same group reported no...
Early experience with 177Lu-PSMA demonstrated PSA decline, both in a multicenter retrospective cohort and in a single-arm phase 2 trial [22], [23]. The international randomized open-label phase III VISION trial tested 177Lu-PSMA-617 plus protocol-permitted standard of care (excluding ...
(17/184) mCRPC patients and PSA-decline of 50% or more in 41.8% (77/184) of the mCRPC patients receiving up to six cycles of [177Lu]Lu-PSMA-617 [8]. Fig. 1 Example of response of [177Lu]Lu-PSMA-617 in a patient with metastatic castration-resistant prostate cancer. On the left...
As expected, the scope of usage of therapeutic PSMA-radioligand therapies such as 177Lu-PSMA-617 and particularly when labeled with alpha-emitters, such as Actinium-225 labeled PSMA-617, can be limited to avoid damage to the glands, thus warranting dose adjustments at the cost of reducing ...